(109 days)
Not Found
Unknown
The summary describes automated image processing and segmentation, which can be performed using traditional algorithms or AI/ML. The document does not explicitly mention AI, ML, or related terms like deep learning or neural networks.
No.
The device is intended for automatic labeling, visualization, and volumetric quantification of brain structures from MR images, used to automate a manual process. It does not provide any treatment or therapy.
Yes
The device aids in the quantification of brain structures and their changes over time, which provides information for clinicians to make diagnostic decisions. It states it can identify differences from a healthy population and in specific patient groups (Alzheimer's, MS, TBI), suggesting its use in supporting diagnosis.
Yes
The device description explicitly states that icobrain is "software" and details its function as an image processing pipeline for analyzing MR images. There is no mention of accompanying hardware components that are part of the medical device itself.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs analyze biological samples: IVDs are designed to examine specimens taken from the human body, such as blood, urine, tissue, etc., to provide information about a person's health.
- This device analyzes medical images: The input for icobrain is MR images, which are generated by a medical imaging scanner, not biological samples.
- The intended use is image processing and quantification: The stated intended use is for automatic labeling, visualization, and volumetric quantification of brain structures from MR images. This is a function of image analysis, not the analysis of biological specimens.
Therefore, while icobrain is a medical device that provides valuable information for clinical use, it does not fit the definition of an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
icobrain is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on MR images.
icobrain consists of two distinct image processing pipelines: icobrain cross and icobrain long.
icobrain cross is intended to provide volumes from images acquired at a single timepoint
icobrain long is intended to provide changes in volumes between two images that were acquired on the same scanner, with the same image acquisition protocol and with same contrast at two different timepoints
The results of icobrain cross cannot be compared with the results of icobrain long.
Product codes
LLZ
Device Description
icobrain is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on MR images.
icobrain consists of two distinct image processing pipelines: icobrain cross and icobrain long.
- icobrain cross is intended to provide volumes from images acquired at a single timepoint
- icobrain long is intended to provide changes in volumes between two images that were acquired on the same scanner, with the same image acquisition protocol and with same contrast at two different timepoints
The results of icobrain cross cannot be compared with the results of icobrain long.
As input, icobrain uses TI-weighted and fluid-attenuated inversion recovery (FLAIR) DICOM MR images from a single or from multiple time points. In case of multiple time points, i.e. multiple MRI scans from the same subject, for each time point one FLAIR and one TI image are used as input. During the pre-processing, the scan type (TI, FLAIR) is detected for every input image before it is converted from DICOM format to NIFTI format. The image processing then performs the actual segmentation and calculates the volumes of the brain structures. In case MRI scans subject on multiple time points are available, the changes in volume of the brain structures are calculated as well. Finally, the computed volumes and volume changes (in case of multiple time points) are summarized into an electronic report and (some) segmentations are overlaid on the input images.
The software displays the following volumetric measures:
- normalized volume and volume changes of the whole brain (sum of white and grey matter),
- normalized volume and volume changes of grey matter,
- unnormalized volume and volume changes of FLAIR white matter hyperintensities.
Normalized whole brain and grey matter volumes are corrected for head size and are compared to a healthy population using a statistical model. The reported FLAIR white matter hyperintensities volumes are not normalized since they are not comparable to a reference population.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
MR images (TI-weighted, FLAIR)
Anatomical Site
Brain
Indicated Patient Age Range
Not Found
Intended User / Care Setting
icobrain is used by trained professionals in hospitals, imaging centers or in image processing labs.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
To demonstrate the performance of icobrain, the measured volume changes of the segmentable brain structures are validated for accuracy and reproducibility. The subjects upon whom the device was tested include healthy subjects, Alzheimer's disease patients, multiple sclerosis patients, traumatic brain injury patients, depression patients.
In the accuracy experiments, the volumes / volume changes are compared to simulated and/or manually labeled ground truth volume changes; in the reproducibility experiments, the volumes / volume changes are compared on test-retest image data sets. A literature review has been performed to set relevant acceptance criteria for each type of experiments passed the acceptance criteria.
The experiments encompassed 349 subject datasets in total. Averaged over all experiments, the Pearson correlation coefficient between the compared measurements was 0.90 and the intraclass correlation coefficient was 0.89.
Besides the validation experiments, verification tests demonstrate the system as a whole provides all the capabilities necessary to operate according to its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Pearson correlation coefficient: 0.90
Intraclass correlation coefficient: 0.89
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized representation of a human figure with three heads, symbolizing health, services, and people. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the figure.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
August 9, 2016
icometrix NV % Mr. Dirk Loeckx CEO Tervuursesteenweg 244 Leuven, B-3001 BELGIUM
Re: K161148
Trade/Device Name: icobrain Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: June 30, 2016 Received: June 30, 2016
Dear Mr. Loeckx:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Michael D'Hara
For
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
510(k) Number (if known) K161148
Device Name icobrain
Indications for Use (Describe)
icobrain is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on MR images.
icobrain consists of two distinct image processing pipelines: icobrain cross and icobrain long.
Icobrain cross is intended to provide volumes from images acquired at a single timepoint
icobrain long is intended to provide changes in volumes between two images that were acquired on the same scanner, with the same image acquisition protocol and with same contrast at two different timepoints
The results of icobrain cross cannot be compared with the results of icobrain long.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (8/14)
PSC Publishing Services (301) 443-6740 EF
3
Image /page/3/Picture/0 description: The image shows the logo for Icometrix, a company specializing in imaging biomarker expertise. The logo features a stylized brain-shaped graphic in shades of blue, green, and red on the left. To the right of the graphic is the company name "icometrix" in a clean, sans-serif font, with the tagline "IMAGING BIOMARKER EXPERTS" in smaller letters underneath.
Section 5. 510(k) Summary
icometrix NV - Kolonel Begauitlaan |b / 12 - 3012 Leuven - Belgium
info@icometrix.com - www.icometrix.com - T +32 16 369 000
IBAN: BE02 7360 2208 4540 - BlC KRED BE BB - BTV/
4
Doc. III5605663.77 (/display/MSMET/Section+5.+510%28k%29+Summary), 2016-09-08 13:34 UTC
- 5.1 Submitter
- 5.2 Device
- • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • Predicate Device
- Device Description
- Intended use
- Comparison of technological characteristics with the predicate device
- 5.7 Performance testing
5. I Submitter
| Name: | icometrix NV |
|---|---|
| Address: | Tervuursesteenweg 244 |
| B-3001 Leuven | |
| Belgium | |
| Contact Person: | Dirk Loeckx |
| Telephone number: | +32 16 369 000 |
| Fax Number: | N.A. |
| E-mail: | dirk.loeckx@icometrix.com |
| Date Prepared: | 21 Jun 2016 |
5.2 Device
| Device Trade Name: | icobrain |
|---|---|
| Common Name | Medical Image Processing Software |
| Classification Name | System, Image processing, Radiological |
| Number | 892.2050 |
| Product Code: | LLZ |
| Classification Panel: | Radiology |
5
5.3 Predicate Device
| Device | NeuroQuantTM |
|---|---|
| 510(k) Number | K061855 |
| Manufacturer | CorTechs Labs, Inc. |
| 4690 Executive Drive, Suite 250 | |
| San Diego, CA 92121 | |
| USA |
5.4 Device Description
icobrain is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on MR images.
icobrain consists of two distinct image processing pipelines: icobrain cross and icobrain long.
- icobrain cross is intended to provide volumes from images acquired at a single timepoint
- icobrain long is intended to provide changes in volumes between two images that were acquired on the same scanner, with the same image acquisition protocol and with same contrast at two different timepoints
The results of icobrain cross cannot be compared with the results of icobrain long.
The following flowchart illustrates the overall architecture of icobrain.
Image /page/5/Figure/9 description: This image is a flowchart that shows the steps involved in image processing. The first step is to input images in DICOM format. The next steps are preprocessing, image processing, and output generation (report/images). The final step is to generate a final report in PDF or DICOM format, as well as output images in DICOM format.
As input, icobrain uses TI-weighted and fluid-attenuated inversion recovery (FLAIR) DICOM MR images from a single or from multiple time points. In case of multiple time points, i.e. multiple MRI scans from the same subject, for each time point one FLAIR and one TI image are used as input. During the pre-processing, the scan type (TI, FLAIR) is detected for every input image before it is converted from DICOM format to NIFTI format. The image processing then performs the actual segmentation and calculates the volumes of the brain structures. In case MRI scans subject on multiple time points are available, the changes in volume of the brain structures are calculated as well. Finally, the computed volumes and volume changes (in case of multiple time points) are summarized into an electronic report and (some) segmentations are overlaid on the input images.
The software displays the following volumetric measures:
- normalized volume and volume changes of the whole brain (sum of white and grey matter),
- normalized volume and volume changes of grey matter,
- unnormalized volume and volume changes of FLAIR white matter hyperintensities.
6
Normalized whole brain and grey matter volumes are corrected for head size and are compared to a healthy population using a statistical model. The reported FLAIR white matter hyperintensities volumes are not normalized since they are not comparable to a reference population.
5.5 Intended use
icobrain is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on MR images.
5.6 Comparison of technological characteristics with the predicate device
| Device | icobrain | NeuroQuantTM |
|---|---|---|
| Regulation | ||
| Number | 21 CFR 892.2050 | 21 CFR 892.2050 |
| Device | ||
| Classification | ||
| Name | System, Image processing, Radiological | System, Image processing, Radiological |
| Product | ||
| Code | LLZ | LLZ |
| Regulatory | ||
| Class | II | II |
| Indications | ||
| for use | icobrain is intended for automatic labeling, visualization and | |
| volumetric quantification of segmentable brain structures from | ||
| a set of MR images. This software is intended to automate the | ||
| current manual process of identifying, labeling and quantifying | ||
| the volume of segmentable brain structures identified on MR | ||
| images. |
Icobrain consists of two distinct image processing pipelines:
icobrain cross and icobrain long.
icobrain cross is intended to provide volumes
from images acquired at a single timepoint icobrain long is intended to provide changes in volumes
between two images that were acquired on the same
scanner, with the same image acquisition protocol and
with same contrast at two different timepoints The results of icobrain cross cannot be compared with the
results of icobrain long. | NeuroQuantTM is intended for automatic labeling, visualization
and volumetric quantification of segmentable brain structures
from a set of MR images. This software is intended to automate
the current manual process of identifying, labeling and
quantifying the volume of segmental brain structures identified
on MR images. |
The device and predicate device (K061855) have an identical classification of:
Table I: Comparison with predicate device
Device and predicate device are software for automatically identifying and quantifying the volumes of brain structures, automatic labeling and visualization. Both devices take 3D MR images of the brain as input and generate an electronic report with similar quantitative information. The output volumes are for both devices compared to a normative dataset computed based on MRI data from normal control subjects.
icobrain and NeuroQuant 11 achieve their intended use based on a similar principle, since the quantification system relies on skull stripping (brain extraction), a brain segmentation based on a
7
probabilistic atlas and image intensity information, and volume calculations of the segmented brain structures. Both devices normalize the volumes to allow the statistical comparison with a normative dataset.
Both devices are DICOM compatible and operate on off-the-shelf hardware.
icobrain is used by trained professionals in hospitals, imaging centers or in image processing labs.
NeuroQuant™ is used by physicians skilled in brain MR imaging.
5.7 Performance testing
To demonstrate the performance of icobrain, the measured volume changes of the segmentable brain structures are validated for accuracy and reproducibility. The subjects upon whom the device was tested include healthy subjects, Alzheimer's disease patients, multiple sclerosis patients, traumatic brain injury patients, depression patients.
In the accuracy experiments, the volumes / volume changes are compared to simulated and/or manually labeled ground truth volume changes; in the reproducibility experiments, the volumes / volume changes are compared on test-retest image data sets. A literature review has been performed to set relevant acceptance criteria for each type of experiments passed the acceptance criteria.
The experiments encompassed 349 subject datasets in total. Averaged over all experiments, the Pearson correlation coefficient between the compared measurements was 0.90 and the intraclass correlation coefficient was 0.89.
Besides the validation experiments, verification tests demonstrate the system as a whole provides all the capabilities necessary to operate according to its intended use.
5.8 Conclusions
The performance testing presented above establishes that the icobrain is safe and effective for its intended use. The comparison above demonstrates that the icobrain device is substantially equivalent to the predicate device.
| Declarations: | This summary includes only information that is also covered in the body of the 510(k). This summary does not contain any puffery or unsubstantiated labeling claims. This summary does not contain any raw data, i.e., contains only summary data. This summary does not contain any trade secret or confidential commercial information. This summary does not contain any patient identification information. |
|---|---|
| --------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
This document is reviewed and approved by Dirk Loeckx, CEO of icometrix, based on the present data and information.
8
Image /page/8/Figure/0 description: The image shows a signature and a date. The signature is a black, stylized mark on a white background. The date is displayed as "04 Aug 2016" next to a calendar icon.